Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sirolimus-Based Immunosuppression vs Tacrolimus After Liver Transplant for Hepatocellular Carcinoma Beyond Milan Criteria
ChiCTR-TRC-11001802Phase 4Completed
- Sponsor
- The Third Medical Center of the Chinese People's Liberation Army General Hospital
- Start
- Sep 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of sirolimus in hepatocellular carcinoma (HCC) (2 arms), sponsored by The Third Medical Center of the Chinese People's Liberation Army General Hospital. Primary endpoint: tumor recurrence rate. Started Sep 2007; status: completed.
02
Drugs
sirolimus
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR-TRC-11001802.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-TRC-11001802.